New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (&#34;Fulcrum Therapeutics&#34; or the

<p>New York, New York--(Newsfile Corp. - August 3, 2026) - <a href="https://api.newsfilecorp.com/redirect/gJgLwhNPVk">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/FULC">FULC</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/ppVRwH3K0E">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/YEjDKFxK1Y"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:jcampisi@kaplanfox.com"><b>jcampisi@kaplanfox.com</b></a><b> or by calling (212) 329-8571.</b></p><p>Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"</p><p>On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik&#174; (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged."  As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."</p><p>Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b></p><p>Jeffrey P. Campisi<br /><a href="https://api.newsfilecorp.com/redirect/0pAXZH5Y4p">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/RYN3KCwvxn">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/WAzNEIn2A0">https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/307667_dd165719f4c918c9_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/qpzWwHMNnX">https://www.newsfilecorp.com/release/307667</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/307667/197" alt="" /></p>

FULC

Kaplan Fox & Kilsheimer LLP Alerts Investors of Fulcrum Therapeutics, Inc. (FULC) to an Investigation of Potential Securities Law Violations

Fulcrum under securities probe as FDA concerns halt pociredir

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (&amp;#34;Fulcrum Therapeutics&amp;#34; or the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kaplan Fox announced a securities investigation into Fulcrum Therapeutics after the June 1 disclosure that pociredir for sickle cell disease has no viable regulatory path due to FDA-concerned PRC2 malignancy risk. The FDA stance, linked to Tazverik-like risks, spurred Fulcrum’s stock to plunge about 51% by June 2. The development raises near-term legal and financing headwinds for this clinical-stage company.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox probes Fulcrum for securities violations. No findings yet.</li><li>Fulcrum discontinues pociredir for SCD after FDA concerns. FDA linked PRC2 risk to malignancies.</li><li>Shares fall 51% after June 1–2 update; June 1 close $6.42, June 2 close $3.14.</li><li>Legal investigation may create near-term financing and partnership headwinds for Fulcrum.</li><li>Industry-wide PRC2 risk could weigh on other programs and investor sentiment.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Fulcrum Therapeutics, Inc. (FULC)</strong>: Subject of ongoing securities investigation; pociredir program halted due to FDA concerns.</li><li><strong>Epizyme, Inc. (EPZM)</strong>: Tazverik (tazemetostat) PRC2 inhibitor; regulatory and safety risks influential to class.</li><li><strong>Bank of America Corp (BAC)</strong>: Referenced in Kaplan Fox&#039;s litigation track record; not directly tied to Fulcrum&#039;s specifics.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on a securities investigation and potential litigation exposure, with ancillary biotech regulatory risk impacting Fulcrum&#039;s development programs and valuation.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Regulatory setback for pociredir increases near-term financing needs.</li><li>Legal investigation may deter partnerships or additional funding discussions.</li><li>Stock volatility remains elevated amid ongoing legal scrutiny.</li><li>PRC2 inhibitor risk could weigh on related biotech programs and valuations.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>June 1, 2026: Fulcrum announces discontinuation of pociredir for SCD.</li><li>FDA concerns cited heightened risk of secondary malignancies for PRC2 inhibitors (e.g., Tazverik).</li><li>March 2026: Tazverik withdrawn from global market due to malignancy risk.</li><li>June 1–2, 2026: FULC shares fall from $6.42 to $3.14, a 51.09% drop.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term bearish: legal probe and regulatory setback could pressure FULC over the next 3–6 months.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - August 3, 2026) - <a href="https://api.newsfilecorp.com/redirect/gJgLwhNPVk">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/FULC">FULC</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/ppVRwH3K0E">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/YEjDKFxK1Y"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:jcampisi@kaplanfox.com"><b>jcampisi@kaplanfox.com</b></a><b> or by calling (212) 329-8571.</b></p><p>Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"</p><p>On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik&#174; (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged."  As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."</p><p>Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b></p><p>Jeffrey P. Campisi<br /><a href="https://api.newsfilecorp.com/redirect/0pAXZH5Y4p">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/RYN3KCwvxn">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/WAzNEIn2A0">https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/307667_dd165719f4c918c9_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/qpzWwHMNnX">https://www.newsfilecorp.com/release/307667</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/307667/197" alt="" /></p>

Kaplan Fox announced a securities investigation into Fulcrum Therapeutics after the June 1 disclosure that pociredir for sickle cell disease has no viable regulatory path due to FDA-concerned PRC2 malignancy risk. The FDA stance, linked to Tazverik-like risks, spurred Fulcrum’s stock to plunge about 51% by June 2. The development raises near-term legal and financing headwinds for this clinical-stage company.

News insight

Kaplan Fox & Kilsheimer LLP Alerts Investors of Fulcrum Therapeutics, Inc. (FULC) to an Investigation of Potential Securities Law Violations

AI summary

Sentiment rationale

Key facts

Legal